Adaptimmune Therapeutics PLC
ADAP
View Detailed Chart
0.055USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
87.31MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-78.30%
Year to Date
-89.81%
1 Year
-90.92%
View Detailed Chart
TradingKey Stock Score of Adaptimmune Therapeutics PLC
Currency: USD Updated: 2025-10-27Key Insights
Adaptimmune Therapeutics PLC's fundamentals are relatively stable, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at max_target_price.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Adaptimmune Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.460
Target Price
+737.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Adaptimmune Therapeutics PLC Highlights
StrengthsRisks
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 555.78% year-on-year.
Overvalued
The company’s latest PE is -0.08, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 83.02M shares, decreasing 51.68% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.88M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 13.28.
Adaptimmune Therapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Adaptimmune Therapeutics PLC Info
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Ticker SymbolADAP
CompanyAdaptimmune Therapeutics PLC
CEORawcliffe (Adrian George)
Websitehttps://www.adaptimmune.com/
FAQs
What is the current price of Adaptimmune Therapeutics PLC (ADAP)?
The current price of Adaptimmune Therapeutics PLC (ADAP) is 0.055.
What is the symbol of Adaptimmune Therapeutics PLC?
The ticker symbol of Adaptimmune Therapeutics PLC is ADAP.
What is the 52-week high of Adaptimmune Therapeutics PLC?
The 52-week high of Adaptimmune Therapeutics PLC is 0.860.
What is the 52-week low of Adaptimmune Therapeutics PLC?
The 52-week low of Adaptimmune Therapeutics PLC is 0.040.
What is the market capitalization of Adaptimmune Therapeutics PLC?
The market capitalization of Adaptimmune Therapeutics PLC is 87.31M.
What is the net income of Adaptimmune Therapeutics PLC?
The net income of Adaptimmune Therapeutics PLC is -70.81M.
Is Adaptimmune Therapeutics PLC (ADAP) currently rated as Buy, Hold, or Sell?
According to analysts, Adaptimmune Therapeutics PLC (ADAP) has an overall rating of --, with a price target of 0.460.
What is the Earnings Per Share (EPS TTM) of Adaptimmune Therapeutics PLC (ADAP)?
The Earnings Per Share (EPS TTM) of Adaptimmune Therapeutics PLC (ADAP) is -0.664.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%Popular Symbols
